Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Clinical Research Coordinator
Lovelace Respiratory Research Institute - Albuquerque, NM
Manager, Strategic Forecasting & Analytics Job
Celgene Corporation - Basking Ridge, NJ, US
Analyst, Procurement Operations Job
Celgene Corporation - Basking Ridge, NJ, US
Clinical Trials Site Director
Lovelace Respiratory Research Institute - Albuquerque, NM
Patient Support Specialist Job
Celgene Corporation - Berkeley Heights, NJ, US

More Jobs >>

Events

Pharmacovigilance and Risk Management Strategies 2012
January 22-25, 2012 — Arlington, Virginia
Just Released: New Trends in Preventive and Therapeutic Vaccine
Enforcement, Litigation and Compliance Conference
Dec. 6-7 — Washington, DC
New Paradigms to Fund & Move Biotech
January 11-12, 2012 — San Francisco, CA

More Events >>

Related Tags >> melanoma

MannKind News

Most Popular MannKind Story

MannKind starts Phase II melanoma vax trial

October 21, 2010 — 6:42am ET | By Maureen Martino

MannKind is best known in the industry for its ongoing attempts to win approval of it's inhaled insulin drug Afrezza. The developer is waiting for a final FDA decision on the drug later this year, Read more...

MannKind Press Releases

MannKind Corporation to Hold 2011 Third Quarter Financial Results Conference Call on November 3, 2011
MannKind to Present at The 18th Annual Newsmakers in the BioTech Industry Conference
MannKind Announces Proposed Offering of Senior Secured Discount Notes Due 2017
MannKind to Present at Rodman & Renshaw Annual Global Investment Conference
MannKind Corporation to Hold 2011 Second Quarter Financial Results Conference Call on August 4, 2011

Latest Headlines

MannKind starts Phase II melanoma vax trial
October 21, 2010

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK